Untreated Hypogonadism and Testosterone Replacement Therapy in Hypogonadal Men Are Associated with a Decreased Risk of Subsequent Prostate Cancer: a Population-based Study

Overview

Journal Int J Impot Res

Specialties Reproductive Medicine
Urology

Date 2024 Jan 4

PMID 38177194

Authors

Kian Asanad

Joshua J Horns

Nathan Driggs

Mary K Samplaski

James M Hotaling

Affiliations

Soon will be listed here.

Abstract

We sought to understand the relationship between hypogonadism and testosterone replacement therapy (TRT) in hypogonadal men on the risk of developing localized and metastatic prostate cancer. We used the Merative MarketScan database of commercial claims encounters to identify men diagnosed with hypogonadism. These men were matched to eugonadal men who served as controls. Multivariate negative binomial regression analysis of prostate cancer diagnoses, hypogonadism, and TRT in hypogonadal men adjusting for various known confounding factors was used to understand the impact of hypogonadism and TRT on prostate cancer risk. We identified 3,222,904 men who met inclusion criteria, of which 50% were diagnosed with hypogonadism (1,611,452) and each were matched to a control (1,611,452). The incidence of prostate cancer was 2.16%, 1.55%, and 1.99% in eugonadal controls, hypogonadal men on TRT, and hypogonadal men without TRT, respectively (p < 0.001). Untreated hypogonadism was independently associated with a decreased risk of localized prostate cancer (IRR 0.46, 95% CI 0.43-0.50, p < 0.001) compared to eugonadal controls. Hypogonadal men on TRT also had a significantly decreased risk of localized prostate cancer (IRR 0.49, 95% CI 0.45-0.53, p < 0.001). Furthermore, hypogonadal men on TRT (IRR 0.21, 95% CI 0.19-0.24, p < 0.001) or without TRT (IRR 0.20, 95% CI 0.18-0.22, p < 0.001) both had significantly decreased risk of metastatic prostate cancer, respectively. Our population-based analysis suggests that untreated hypogonadism in men is associated with a 50% decreased incidence of localized prostate cancer and an 80% decreased incidence of metastatic prostate cancer. TRT in hypogonadal men was also associated with a decreased risk of subsequent prostate cancer. Further research is needed to better understand the relationship between hypogonadism and TRT in hypogonadal men on the risk of subsequent prostate cancer.

References

Khoo E, Tan H, Low W . Erectile dysfunction and comorbidities in aging men: an urban cross-sectional study in Malaysia. J Sex Med. 2008; 5(12):2925-34. DOI: 10.1111/j.1743-6109.2008.00988.x. View

Ponholzer A, Madersbacher S, Rauchenwald M, Jungwirth S, Fischer P, Tragl K . Vascular risk factors and their association to serum androgen levels in a population-based cohort of 75-year-old men over 5 years: results of the VITA study. World J Urol. 2009; 28(2):209-14. DOI: 10.1007/s00345-009-0440-y. View

Wong S, Chan D, Hong A, Woo J . Prevalence of and risk factors for androgen deficiency in middle-aged men in Hong Kong. Metabolism. 2006; 55(11):1488-94. DOI: 10.1016/j.metabol.2006.06.019. View

Mulligan T, Frick M, Zuraw Q, Stemhagen A, McWhirter C . Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60(7):762-9. PMC: 1569444. DOI: 10.1111/j.1742-1241.2006.00992.x. View

Mulhall J, Trost L, Brannigan R, Kurtz E, Redmon J, Chiles K . Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018; 200(2):423-432. DOI: 10.1016/j.juro.2018.03.115. View

Anaissie J, DeLay K, Wang W, Hatzichristodoulou G, Hellstrom W . Testosterone deficiency in adults and corresponding treatment patterns across the globe. Transl Androl Urol. 2017; 6(2):183-191. PMC: 5422691. DOI: 10.21037/tau.2016.11.16. View

Fendereski K, Ghaed M, Calvert J, Hotaling J . Hypogonadism and urologic surgeries: a narrative review. Transl Androl Urol. 2022; 11(7):1045-1062. PMC: 9360521. DOI: 10.21037/tau-22-308. View

Muller R, Gerber L, Moreira D, Andriole G, Castro-Santamaria R, Freedland S . Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012; 62(5):757-64. DOI: 10.1016/j.eururo.2012.05.025. View

Watts E, Appleby P, Perez-Cornago A, Bueno-de-Mesquita H, Chan J, Chen C . Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. Eur Urol. 2018; 74(5):585-594. PMC: 6195673. DOI: 10.1016/j.eururo.2018.07.024. View

10.

Baillargeon J, Kuo Y, Fang X, Shahinian V . Long-term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer. J Urol. 2015; 194(6):1612-6. DOI: 10.1016/j.juro.2015.05.099. View

11.

Walsh T, Shores M, Krakauer C, Forsberg C, Fox A, Moore K . Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels. PLoS One. 2018; 13(6):e0199194. PMC: 6014638. DOI: 10.1371/journal.pone.0199194. View

12.

Shabsigh R, Crawford E, Nehra A, Slawin K . Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2008; 21(1):9-23. DOI: 10.1038/ijir.2008.31. View